Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
:CYTK
CYTK Stock Chart & Stats
$60.18
-$0.99(-2.05%)
At close: 4:00 PM EST
$60.18
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$29.31 - $63.86
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.22M
Market Cap
$6.92B
Enterprise Value$3.95B
Total Cash (Recent Filing)$858.13M
Total Debt (Recent Filing)$858.06M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 05, 2025EPS Estimate
-1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding119,657,160
10 Day Avg. Volume1,697,856
30 Day Avg. Volume2,223,187
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue46.01
Enterprise Value/Gross Profit-20.27
Enterprise Value/Ebitda-7.81
Forecast
1Y Price Target
$81.00Price Target Upside34.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Commercial Launch InitiativesCytokinetics anticipates ~$729M in net proceeds from the convertible note offering, supporting aficamten commercial launch initiatives and other R&D milestones.
Financial PerformanceCytokinetics executed on a $650M upsized convertible note offering to refinance the majority portion of the 2027 convertible notes into 2031, at an attractive 1.75% coupon rate and conversion price at ~38% premium to $50 share price.
Market Share PotentialCytokinetics shares have rallied ~37% on the heels of a home-run scenario delivered at the ESC'25 conference, supportive of the prospects of aficamten's long-term market share gains within the obstructive hypertrophic cardiomyopathy class.
Bears Say
Competition And Market DynamicsBroad, front-line use of a cardiac myosin inhibitor is unlikely due to the well-established profile of beta-blockers.
Formulary Approval DifficultiesFormulary exceptions can be difficult, with approval rates around 40%, discouraging doctors from prescribing non-covered options.
Regulatory ChallengesFDA’s move to approve afi with a REMS remains an overhang, potentially challenging Cytokinetics’ goal of growing share/category.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $63.86 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $6.92B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Nov 05, 2025 which is in 7 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 07, 2025. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.43 by $0.31.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.57.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,657,160 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.43. Following the earnings report the stock price went down -3.234%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.00 (34.60% Upside)
$81.00 (34.60% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 118.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.57%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and other therapeutics to treat debilitating diseases and medical conditions that affect muscle function. The company operates primarily in the sectors of neuromuscular diseases and cardiovascular diseases, with core products that include its lead drug candidates designed to enhance muscle contractility and improve overall muscle performance.
CYTK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant advancements in clinical trials, regulatory progress, and sales force readiness. However, these were countered by financial challenges, including increased expenses and a net loss, as well as a delayed PDUFA date impacting timelines for aficamten's approval.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$81.00
▲(34.60% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
0.74% Insiders
39.85% Mutual Funds
0.20% Other Institutional Investors
36.22% Public Companies and Individual Investors